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Common genetic susceptibility variants could be used for risk stratification in risk-tailored cancer 
screening and prevention programmes.  Combining genetic variants with environmental risk factors 
would improve risk stratification.  Epigenetic changes are surrogate markers of environmental 
exposures during individual’s lifetime.  Integrating epigenetic markers, in lieu of environmental 
exposure data, with genetic markers would potentially improve risk stratification.  Epigenetic 
changes are reversible and acquired gradually, providing potentials for prevention and early 
detection strategies.  The epigenetic changes are tissue-specific and stage-of-development-specific, 
raising challenges in choice of sample and timing for evaluation of cancer-associated changes.  The 
Horizon 2020 funded research programme, FORECEE, using empirical data, will investigate the value 
of integration of epigenomics with genomics for risk prediction and prevention of women-specific 
cancers.  
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To date, model-based estimates have shown the potential utility of common genetic susceptibility 
loci for risk-stratification in cancer prevention and screening programmes at population level [1;2].  
A risk stratified screening strategy has the potential to improve the efficiency of the screening 
programme and reduce its adverse consequences.  For example, a risk-stratified screening strategy 
for breast cancer with eligibility for screening based on an absolute risk that is dependent on age 
and polygenic risk-profile has been shown to reduce the number of women invited to screening 
while detecting most cancers potentially detectable by a conventional age-based screening strategy 
[1].  Studies in prostate cancer have shown that targeting screening to men at higher than 
population average risk, based on polygenic risk, could reduce the proportion of prostate cancers 
likely to be overdiagnosed [3;4].  
A risk-stratified prevention or screening programme would involve risk assessment, then stratifying 
the population into several risk groups and offering the intervention differentially to each population 
stratum with the expectation of improving the benefit – harm balance of the intervention [5].  
Interventions, like screening, would be risk-tailored, with varying start and end age, frequency, and 
modality of screening [6].  
For risk assessment, genetic and environmental risk factors could be used.  A broad definition of 
environment includes lifestyle, nutrition, external environmental exposures, and reproductive 
history [7].  To date, genome-wide association studies have identified 94 breast cancer susceptibility 
variants [8].  The polygenic risk profile based on these variants has area under the receiver operator 
characteristic curve (AUC-ROC) of 0.65.  AUC-ROC is the probability that a test correctly identifies an 
individual who will develop the disease from a pair of whom one will be affected and one will remain 
unaffected.  AUC-ROC values range from 0.5 (total lack of discrimination) to 1.0 (perfect 
discrimination) [9].  Combining polygenic risk with environmental risk factors, like age of menarche, 
number of births, age of first live birth, oral contraceptive use, body mass index, alcohol, smoking, 
personal history of benign breast disease, and family history of breast cancer in first-degree relatives 
[2], would increase AUC-ROC to 0.68.  Even a modest increase in AUC-ROC  following combining genetic 
with environmental risk factors would substantially improve risk-stratification [2]. 
Epigenome as readout for environmental exposures  
Age, environmental exposures (such as tobacco, alcohol, infectious agents) and endogenous stimuli 
(such as circulating hormones) can trigger alterations in the epigenetic pattern.  These alterations 
affect gene expression without changing the nucleotide sequence.  Epigenetic changes are generally 
stable and propagate over cell divisions resulting in changes in phenotype. The predominant 
mechanisms that may act alone or in combination to regulate gene expression over the lifetime of 
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an organism include DNA methylation, histone modification, microRNA (miRNA) expression and 
processing, and chromatin condensation [10].   
Epigenetic mechanisms are implicated in the initiation and progression of cancer through tumour 
suppressor genes silencing and / or oncogenes activation.  DNA methylation is the most studied 
mechanism of epigenetic gene regulation [11].  DNA methylation refers to the addition of methyl 
group to cytosine base that is located 5’ to a guanosine base in a CpG dinucleotide.  Regions of the 
genome rich in CpG are known as CpG islands, which are found in the promotor region of 
approximately half of all genes.  Aberrant promotor hypermethylation associated with inappropriate 
gene silencing plays important role in tumour progression [12].  Whereas genome-wide decrease in 
methylation may lead to genomic instability and is associated with tumour progression [13].    
Environmental exposures may promote tumour development by inducing both epigenetic and 
genetic changes (like mutations).  The epigenetic make-up may play a role in the cellular response to 
these environmental exposures.  Epigenetics may mediate or modify genetic risk [14].  As such 
individual’s susceptibility to cancer would depend on both genetics and epigenetics make-up [15].  
Opportunities and challenges  
Epigenetic changes unlike the genetic ones are reversible and can be modulated for example by diet, 
drugs, and other environmental factors.  This reversibility provides opportunity for cancer 
prevention strategies [10].    
Environmentally triggered epigenetic changes are acquired gradually and influence tumour initiation 
and progression.  In cervical cancer, epigenetic changes have been detected in morphologically 
normal cells years in advance of neoplastic transformation [16].  DNA methylation has been shown 
to be differentially variable between normal, intra-epithelial neoplasia, and invasive cervical cancers 
[17]. In esophageal cancer, DNA methylation profile has been shown to predict progression of 
dysplasia in Barrett’s esophagus [18]. These indicate that epigenetic changes could be used for risk 
prediction and early diagnosis.  
Epigenetic alterations can act as surrogate markers of environmental exposures during individual’s 
lifetime. Information collected on environmental exposures via questionnaire or direct 
measurement is susceptible to recall bias and to inadequate capturing of exposures with short half-
lives and of low biological dose.  Epigenetic markers when used in lieu could overcome some of 
these limitations [14].   As combining polygenic risk with environmental risk factors improves risk 
stratification, then integration of epigenetic markers and polygenic risk into a risk assessment tool 
would potentially improve risk stratification in cancer screening and prevention programmes.  
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Unlike the genome, which is the same for all types of cells, the epigenome varies across cell types, in 
the same cell at different developmental stage, under the influence of different environmental 
exposures, and over time.   For example, buccal cells exhibit significantly more smoking associated 
DNA methylation changes than blood cells.  These changes correlate with DNA methylation changes 
in epithelial cancers and particularly with smoke related epithelial cancers, notably lung cancer [19].  
The tissue-specificity of the epigenetic changes raises an issue with accessing tissue samples from 
organs like the prostate, ovary, breast, which are inaccessible by non-invasive means.  Alternatively, 
tissue surrogates could be used.  For example, epithelial cells from the uterine cervix are hormone 
sensitive and are likely to capture an ‘epigenetic record’ of breast cancer risk factors, and hence 
could be used as surrogate for breast cancer cells [20].  
This plasticity of the epigenome poses several challenges in epigenetic testing.  While polygenic risk 
could be determined at any point in time, a risk score that includes epigenetic markers needs to be 
evaluated several times to follow cancer-associated alterations.  To identify a risk marker, it is 
important to differentiate between association and causality of epigenetic mark with disease [10], 
that is whether a change is adaptive response to environmental exposures or adverse effect with 
phenotypic consequences [15].  International efforts, such as the International Human Epigenome 
Consortium, and the reference epigenome, will enable comparison and identification of adverse 
effects [15].  
Integration of different types of genomic, epigenomic, and epidemiological data would be 
challenging.  To overcome this, there is need for engaging geneticists, bioinformaticians, 
statisticians, and clinicians and for developing improved strategies for handling large databases, data 
analysis and interpretation.  
Future perspectives  
The European Commission Framework Programmes, Horizon 2020, recently funded the multi-
disciplinary research programme, FORECEE (Female cancer prediction using cervical omics to 
individualise screening and prevention) (http://cordis.europa.eu/search/result_en?q=forecee) to 
assess the validity, public health utility, cost-effectiveness, acceptability, and ethical, legal, social and 
regulatory impacts of using genomics, epigenomics, and metagenomics data in personalized 
screening and prevention programmes for breast, ovarian, endometrial and cervical cancers.  To 
discover new DNA methylation signatures, an epigenome wide association study (EWAS) will be 
conducted using prospectively collected cervical cells from liquid based cytology cervical smears.  
Women’s cancer risk identification test that combines DNA methylation signatures with SNPs and 
the microbiome will be developed and validated to predict the absolute risk of developing breast, 
6 
 
ovarian, endometrial or cervical cancer.  In the coming four years, the multidisciplinary team with 
expertise in oncology, genetics, genetics statistics, omics technologies, bioinformatics, decision 
analysis, epidemiology, public health, health economics, ethics, risk communication, will be 
addressing the challenges with developing and implementing omics based cancer prevention and 
screening programme. 
Conclusion  
Cancer is a genetic and epigenetic disease. Combining genetic and epigenetic markers provides huge 
potentials for risk stratification in cancer control programmes.  Multi-disciplinary efforts are needed 
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